Immunoliposomes As a Promising Antiviral Agent against SARS-CoV-2

Area of Science:

• Virology
• Immunology
• Drug Development

Background:

• The Russian Federation reported over 23 million COVID-19 cases and 400,000 deaths between 2020 and 2023.
• High mutation rates in SARS-CoV-2, including new strains like Eris and Pyrola, necessitate novel antiviral strategies.
• The mutating receptor-binding domain presents significant challenges for existing treatments.

Purpose of the Study:

• To develop a new immunoliposomal drug candidate for treating COVID-19.
• To target the SARS-CoV-2 S protein using a specific monoclonal antibody.
• To enhance the delivery of ribonuclease into infected cells for viral RNA degradation.

Main Methods:

• Development of an immunoliposomal drug encapsulating ribonuclease.
• Targeting the SARS-CoV-2 S protein with the P4A1 monoclonal neutralizing antibody.
• Assaying the neutralizing activity of the drug compared to the free antibody.

Main Results:

• The developed immunoliposomal drug demonstrated enhanced neutralizing activity against SARS-CoV-2.
• A significant increase, over 40-fold, in neutralizing activity was observed compared to the free monoclonal antibody.
• The drug effectively delivers ribonuclease into virus-infected cells.

Conclusions:

• The novel immunoliposomal drug shows promise as a potent antiviral agent against SARS-CoV-2.
• This approach offers a new strategy for combating rapidly mutating viruses like SARS-CoV-2.
• Further research is warranted to explore its therapeutic potential in clinical settings.